公开(公告)号：EP3368068B1

公开(公告)日：2020-11-18

申请号：EP16801955.2

申请日：2016-10-28

申请人： University of Copenhagen

发明人： BERTELSEN, Adam Frederik Sander ,  SALANTI, Ali ,  THEANDER, Thor ,  THRANE, Susan ,  MIKKEL JANITZEK, Christoph ,  ØRSKOV AGERBÆK, Mette ,  AGERTOUG NIELSEN, Morten

IPC分类号： A61K39/00 ,  A61K39/015 ,  C12N7/00

公开(公告)号：EP3122774B1

公开(公告)日：2020-11-04

申请号：EP15711775.5

申请日：2015-03-24

申请人： Yale University ,  GlaxoSmithKline Biologicals S.A.

发明人： BUCALA, Richard ,  GEALL, Andrew

IPC分类号： A61K39/00 ,  A61K39/015 ,  C07K16/20 ,  C07K16/24 ,  C07K14/44

公开(公告)号：EP3405582B1

公开(公告)日：2020-08-12

申请号：EP17701449.5

申请日：2017-01-19

申请人： Janssen Vaccines & Prevention B.V.

发明人： CUSTERS, Jerôme, H.H.V. ,  VELLINGA, Jort ,  VUJADINOVIC, Marija ,  VAN DER HELM, Esmeralda

IPC分类号： C12N15/86 ,  A61K39/015

公开(公告)号：EP3624843A1

公开(公告)日：2020-03-25

申请号：EP18728968.1

申请日：2018-05-11

申请人： King Abdullah University Of Science And Technology

发明人： PAIN, Arnab ,  CULLETON, Richard ,  ILLINGWORTH, Christopher J.R.

IPC分类号： A61K39/015 ,  C07K14/445

公开(公告)号：EP2956166B1

公开(公告)日：2019-01-16

申请号：EP14743724.8

申请日：2014-01-24

申请人： Sanaria Inc. ,  Academisch Ziekenhuis Leiden ,  Stichting Katholieke Universiteit

发明人： JANSE, Chris J. ,  ANNOURA, Takeshi ,  KHAN, Shahid M. ,  VAN SCHAIJK, Ben ,  PLOEMEN, Ivo HJ ,  VOS, Martijn W. ,  SAUERWEIN, Robert

IPC分类号： A61K39/015

公开(公告)号：EP2988776B1

公开(公告)日：2018-12-26

申请号：EP14719741.2

申请日：2014-04-24

申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

发明人： BOES, Alexander ,  SPIEGEL, Holger ,  GÜVEN, Edgü ,  BEISS, Veronique ,  SACK, Markus ,  REIMANN, Andreas ,  FISCHER, Rainer

IPC分类号： A61K39/002 ,  A61K39/015 ,  C12N15/62

CPC分类号： C07K14/445 ,  A61K39/002 ,  A61K39/015 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/62 ,  Y02A50/412

摘要： The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

公开(公告)号：EP3412306A2

公开(公告)日：2018-12-12

申请号：EP18168155.2

申请日：2010-08-18

申请人： Rockefeller University

发明人： SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

IPC分类号： A61K39/015

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/861 ,  C12N2710/10322 ,  C12N2710/10341 ,  C12N2710/10343 ,  Y02A50/412

摘要： The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

公开(公告)号：EP3368068A1

公开(公告)日：2018-09-05

申请号：EP16801955.2

申请日：2016-10-28

申请人： The University of Copenhagen

发明人： FREDERIK SANDER PEDERSEN, Adam ,  SALANTI, Ali ,  THEANDER, Thor ,  THRANE, Susan ,  MIKKEL JANITZEK, Christoph ,  ØRSKOV AGERBÆK, Mette ,  AGERTOUG NIELSEN, Morten

IPC分类号： A61K39/00 ,  A61K39/015 ,  C12N7/00

摘要： The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.

公开(公告)号：EP3313807A1

公开(公告)日：2018-05-02

申请号：EP16741391.3

申请日：2016-06-27

申请人： Universidade do Porto ,  Instituto de Higiene e Medicina Tropical ,  Instituto Politécnico Do Porto

发明人： DA COSTA LEÃO, Pedro Nuno ,  MARTINS, Maria Do Rosário ,  COSTA, Margarida ,  VASCONCELOS, Vítor ,  DOMINGUES, Valentina ,  NOGUEIRA, Fátima

IPC分类号： C07C43/23 ,  A61K31/09 ,  A61K39/015 ,  C12N1/00

摘要： The present disclosure relates to compounds and compositions for the treatment of malarian diseases. The compounds comprise a class of halogenated alkyl-aromatic secondary metabolites, including hierridic C, or pharmaceutically acceptable salts, esters, solvates or prodrugs thereof. The compounds comprise a halogen; C1-C6 alkyl, H, COCH3, COH, CO-alkyl, or CO-aryl; and a C3-C30 alkyl. In at least one embodiment, the compound is 3-chloro-4,6-dimethoxy-2-pentadecylphenol. The present disclosure also relates to methods of obtain the compounds from a solution comprising a cyanobacterium.

公开(公告)号：EP3309251A1

公开(公告)日：2018-04-18

申请号：EP16807639.6

申请日：2016-06-13

申请人： Mie University ,  BioComo Inc.

发明人： NOSAKA, Tetsuya ,  TSURUDOME, Masato ,  FUKUMURA, Masayuki ,  OHTSUKA, Junpei ,  YUDA, Masao ,  IWANAGA, Shiroh

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/015 ,  A61K39/02 ,  A61K39/04 ,  A61K39/12 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  C07K14/115

CPC分类号： A61K39/155 ,  A61K39/00 ,  A61K39/015 ,  A61K39/02 ,  A61K39/04 ,  A61K39/12 ,  C07K14/115 ,  C12N7/00 ,  C12N15/09 ,  C12N15/86 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/392 ,  Y02A50/394 ,  Y02A50/412

摘要： The present invention relates to: a virus vector, which can effectively transfer a macromolecular antigenic peptide into target cells while maintaining a three-dimensional structure that is required for functioning as an antigen; and a vaccine utilizing the vector. Specifically, disclosed are: a virus vector, in which a nucleic acid encoding an antigenic polypeptide is integrated immediately 5' upstream of HN gene of an F gene-defective Paramyxoviridae virus gene, wherein the antigenic polypeptide is expressed as a fusion protein of 130 or more amino acid residues, fused with a TM sequence and/or a CT sequence derived from the virus.

摘要翻译： 本发明涉及一种病毒载体，其能够维持作为抗原发挥功能所需要的三维结构，并且能够有效地将大分子抗原肽转移到靶细胞中， 和利用该载体的疫苗。 具体而言，公开了一种病毒载体，其中编码抗原性多肽的核酸立即整合到F基因缺陷型副粘病毒科病毒基因的HN基因的5'上游，其中该抗原性多肽表达为融合蛋白130或 与TM序列融合的更多氨基酸残基和/或来自病毒的CT序列。